CTLA4 and melanoma: In another cohort of melanoma patients who received anti-CTLA4 or anti-CTLA4 + anti-PD1 therapy (n = 35) [44], Hypo-MS4 was consistently associated with poor responses but was less significant (Fig. 5D, right panel, P = 0.36).